@DrNickTwit @lucytobin Interestingly a similar case diagnosed at almost 6 months of age by a similar project in Australia https://t.co/W4I0nwxhho
RT @econ_genomics: Long-term economic impacts of exome sequencing for suspected monogenic disorders: diagnosis, management, and reproductiv…
Long-term economic impacts of exome sequencing for suspected monogenic disorders: diagnosis, management, and reproductive outcomes | feat. @ZornitzaS | https://t.co/iOUsa24MJu #healtheconomics
RT @GIMJournal: Exome sequencing is cost-effective, especially when cascade testing and reproductive outcomes are considered https://t.co/Z…
RT @GIMJournal: Exome sequencing is cost-effective, especially when cascade testing and reproductive outcomes are considered https://t.co/Z…
RT @MuinJKhoury: What's the long-term economic impact of exome sequencing for the diagnosis and management of suspected rare diseases? Via…
RT @GIMJournal: Exome sequencing is cost-effective, especially when cascade testing and reproductive outcomes are considered https://t.co/Z…
RT @ZornitzaS: Making the case for early diagnosis #RareDisease #genomics #healtheconomics First end-to-end CEA incl 20yr projection: when…
RT @ZornitzaS: Making the case for early diagnosis #RareDisease #genomics #healtheconomics First end-to-end CEA incl 20yr projection: when…
RT @MuinJKhoury: What's the long-term economic impact of exome sequencing for the diagnosis and management of suspected rare diseases? Via…
What's the long-term economic impact of exome sequencing for the diagnosis and management of suspected rare diseases? Via @GIMJournal https://t.co/nVeo6qd0ne https://t.co/DVnsk5pO9E
RT @GIMJournal: Exome sequencing is cost-effective, especially when cascade testing and reproductive outcomes are considered https://t.co/Z…
RT @ZornitzaS: Making the case for early diagnosis #RareDisease #genomics #healtheconomics First end-to-end CEA incl 20yr projection: when…
RT @ZornitzaS: Making the case for early diagnosis #RareDisease #genomics #healtheconomics First end-to-end CEA incl 20yr projection: when…
RT @ZornitzaS: Making the case for early diagnosis #RareDisease #genomics #healtheconomics First end-to-end CEA incl 20yr projection: when…
RT @ZornitzaS: Making the case for early diagnosis #RareDisease #genomics #healtheconomics First end-to-end CEA incl 20yr projection: when…
Impactful economic analysis of ES
RT @GIMJournal: Exome sequencing is cost-effective, especially when cascade testing and reproductive outcomes are considered https://t.co/Z…
RT @ZornitzaS: Making the case for early diagnosis #RareDisease #genomics #healtheconomics First end-to-end CEA incl 20yr projection: when…
RT @GIMJournal: Exome sequencing is cost-effective, especially when cascade testing and reproductive outcomes are considered https://t.co/Z…
RT @GIMJournal: Exome sequencing is cost-effective, especially when cascade testing and reproductive outcomes are considered https://t.co/Z…
RT @ZornitzaS: Making the case for early diagnosis #RareDisease #genomics #healtheconomics First end-to-end CEA incl 20yr projection: when…
RT @GIMJournal: Exome sequencing is cost-effective, especially when cascade testing and reproductive outcomes are considered https://t.co/Z…
RT @GIMJournal: Exome sequencing is cost-effective, especially when cascade testing and reproductive outcomes are considered https://t.co/Z…
RT @ZornitzaS: Making the case for early diagnosis #RareDisease #genomics #healtheconomics First end-to-end CEA incl 20yr projection: when…
RT @ZornitzaS: Making the case for early diagnosis #RareDisease #genomics #healtheconomics First end-to-end CEA incl 20yr projection: when…
RT @ZornitzaS: Making the case for early diagnosis #RareDisease #genomics #healtheconomics First end-to-end CEA incl 20yr projection: when…
RT @ZornitzaS: Making the case for early diagnosis #RareDisease #genomics #healtheconomics First end-to-end CEA incl 20yr projection: when…
RT @GIMJournal: Exome sequencing is cost-effective, especially when cascade testing and reproductive outcomes are considered https://t.co/Z…
RT @ZornitzaS: Making the case for early diagnosis #RareDisease #genomics #healtheconomics First end-to-end CEA incl 20yr projection: when…
RT @GIMJournal: Exome sequencing is cost-effective, especially when cascade testing and reproductive outcomes are considered https://t.co/Z…
“Use of ES in suspected monogenic disorders becomes increasingly cost-effective as the benefits of ES data reanalysis, cascade testing in first-degree relatives, and parental reproductive outcomes are incorporated into modeling”
Making the case for early diagnosis #RareDisease #genomics #healtheconomics First end-to-end CEA incl 20yr projection: when family outcomes taken into account 36 QALYs gained, ICER AU$14,235
RT @GIMJournal: Exome sequencing is cost-effective, especially when cascade testing and reproductive outcomes are considered https://t.co/Z…
RT @GIMJournal: Exome sequencing is cost-effective, especially when cascade testing and reproductive outcomes are considered https://t.co/Z…
Exome sequencing is cost-effective, especially when cascade testing and reproductive outcomes are considered https://t.co/ZNBfdvIGpI https://t.co/5e2dOxPAre
RT @ZornitzaS: #healtheconomics #raredisease #genomics @GIMJournal: first end-to-end CEA incl #QALY demonstrating long term health and ec…
RT @ZornitzaS: #healtheconomics #raredisease #genomics @GIMJournal: first end-to-end CEA incl #QALY demonstrating long term health and ec…
Exome sequencing is cost-effective in the diagnosis and management of rare diseases. #PrecisionMedicine #genomics https://t.co/eIDSYm84vn
RT @ZornitzaS: #healtheconomics #raredisease #genomics @GIMJournal: first end-to-end CEA incl #QALY demonstrating long term health and ec…
RT @ZornitzaS: #healtheconomics #raredisease #genomics @GIMJournal: first end-to-end CEA incl #QALY demonstrating long term health and ec…
RT @ZornitzaS: #healtheconomics #raredisease #genomics @GIMJournal: first end-to-end CEA incl #QALY demonstrating long term health and ec…
RT @ZornitzaS: #healtheconomics #raredisease #genomics @GIMJournal: first end-to-end CEA incl #QALY demonstrating long term health and ec…
This is very useful to justify to the payors, govt and insurance alike.
RT @ZornitzaS: #healtheconomics #raredisease #genomics @GIMJournal: first end-to-end CEA incl #QALY demonstrating long term health and ec…
RT @ZornitzaS: #healtheconomics #raredisease #genomics @GIMJournal: first end-to-end CEA incl #QALY demonstrating long term health and ec…
RT @ZornitzaS: #healtheconomics #raredisease #genomics @GIMJournal: first end-to-end CEA incl #QALY demonstrating long term health and ec…
RT @ZornitzaS: #healtheconomics #raredisease #genomics @GIMJournal: first end-to-end CEA incl #QALY demonstrating long term health and ec…
RT @ZornitzaS: #healtheconomics #raredisease #genomics @GIMJournal: first end-to-end CEA incl #QALY demonstrating long term health and ec…
RT @ZornitzaS: #healtheconomics #raredisease #genomics @GIMJournal: first end-to-end CEA incl #QALY demonstrating long term health and ec…
RT @ZornitzaS: #healtheconomics #raredisease #genomics @GIMJournal: first end-to-end CEA incl #QALY demonstrating long term health and ec…
RT @jsantoyo: Long-term economic impacts of exome sequencing for suspected monogenic disorders: diagnosis, management, and reproductive out…
Long-term economic impacts of exome sequencing for suspected monogenic disorders: diagnosis, management, and reproductive outcomes. https://t.co/kgj6Spno33
RT @ZornitzaS: #healtheconomics #raredisease #genomics @GIMJournal: first end-to-end CEA incl #QALY demonstrating long term health and ec…
RT @ZornitzaS: #healtheconomics #raredisease #genomics @GIMJournal: first end-to-end CEA incl #QALY demonstrating long term health and ec…
#healtheconomics #raredisease #genomics @GIMJournal: first end-to-end CEA incl #QALY demonstrating long term health and economic benefits of early diagnosis @MelbGenomics @TeamVCGS @MCRI_for_kids https://t.co/BqIDjYhCRZ
Study evaluates the cost-effectiveness of exome sequencing infants for rare disease diagnosis https://t.co/5oWd25Hwqq @GIMJournal